Global pharmaceutical leader Lupin Limited (Lupin) will showcase data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, scheduled from October 17 to 21, 2025
The presentation, titled “A Phase 1 Dose Escalation Study of LNP3693 (STING Agonist) in Patients with Advanced or Metastatic Solid Tumors & Lymphoma,” will be part of the Investigational Immunotherapy session (Presentation Number 1553P) and can be viewed on October 19, 2025, from 09:00 to 17:00 CEST.
LNP3693 is an investigational parenteral STING agonist. The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors.
"This marks another important milestone for us. Following our successful presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, it is a privilege to present the findings of another Phase 1 clinical trial for LNP3693, a STING agonist, at ESMO. ESMO's acknowledgment of the clinical research conducted in India underscores the proficiency of our team in oncology drug discovery, research, and clinical development," said Vinita Gupta, CEO, Lupin.
Presentation Details:
· Date & Time: Sunday, October 19, 2025, 09:00–17:00 (CEST)
· Session Title: A Phase 1 Dose Escalation Study of LNP3693 (STING Agonist) in Patients with Advanced or Metastatic Solid Tumors & Lymphoma
· Category: Investigational Immunotherapy
· Clinical Trial Registration Number: CTRI/2023/10/059147
· Presentation Number: 1553P
Complete data has been provided for presentation at ESMO 2025 and will be discussed during the official session.
All abstracts accepted for presentation at ESMO 2025 will be published online via the ESMO website on Monday, October 13, at 6:05 p.m. ET (12:05 a.m. CEST). Accepted abstracts will also appear in the ESMO Congress 2025 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.